Get ready for the rebirth of Google Glass. Details were recently uncovered that indicate Google is working on an upgraded version. However not aimed at the general consumer, but at the enterprise market.

According to 9to5google, this upcoming edition will pack a larger display prism, Intel Atom CPU and the ability to connect an external battery pack — all upgrades critical for enterprise users.

This model, if real, would be sold to companies looking to equip their workforce with smarter technology. Instead of receiving tweets, these users would get information related to their job. Think warehouse workers. With this version of Google Glass, these works would be able to receive and process orders quicker.

Reportedly the new version of Google Glass also sports improved battery life, partly because of the Intel Atom CPU. The specific clock speed is unknown, but this tiny SoC has proven itself by powering most Android Wear devices. The inclusion of an optional battery pack states Google is aiming this device at industries looking for constant all-day use.

This isn’t the first time an Enterprise-focused Google Glass was uncovered. The WSJ reported in late 2014 that Google was retooling Glass for such a use case and would release the model in 2015.

Apogee Silver Ltd. announces a proposed consolidation of its common shares as approved by shareholders at its annual and special meeting held June 17, 2014 (the “Meeting”). At the Meeting shareholders approved a special resolution to amend the articles of incorporation of the Company to consolidate its issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-consolidated Common Share for up to a maximum of one hundred (100) pre-consolidated Common Shares, at the discretion of the Board for a period of one year following the Meeting. Upon review and approval of the Board of Directors, the Company proposes that it consolidates its Common Shares such that one (1) new post-consolidated Common Share would be issued for every sixty-five (65) Common Shares outstanding on the effective date of the consolidation, or such lower number as may be required to obtain approval of the TSX Venture Exchange.

Apogee currently has 450,816,059 Common Shares outstanding. Following the completion of the share consolidation on a sixty-five to one basis, Apogee would have approximately 6,935,631 Common Shares issued and outstanding. The change in the number of issued and outstanding common shares that would result from the share consolidation would not materially affect any shareholder’s percentage ownership in Apogee, although such ownership would be represented by a smaller number of common shares.

The proposed share consolidation is subject to the approvalof the TSX Venture Exchange.

About Apogee Silver Ltd.

Apogee Silver Ltd. is a mineral exploration and development stage company listed on the TSX Venture Exchange under the symbol APE. Apogee targets advanced, high grade silver-zinc-lead projects in South America. Currently its projects are located in the historic silver producing regions of northern Chile.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Statements containing forward-looking information express, as at the date of this news release, the Transaction, the Company’s plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and the Company does not intend, and does not assume any obligation to, update such statements containing the forward-looking information. Such forward-looking statements and information include, but are not limited to statements as to: anticipated timing with respect to the implementation of the share consolidation, the effects of the share consolidation, the accuracy of estimated mineral reserves and resources, anticipated results of future exploration, and forecast future metal prices, and expectations that environmental, permitting, legal, title, taxation, socio-economic, political, marketing or other issues will not materially affect estimates of mineral reserves. These statements reflect the company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.

These statements reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.
Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained in this news release and the company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: statements with respect to the proposed share consolidation, risks related to the technological and operational nature of the company’s business; changes in national and local government, legislation, taxation, controls or regulations and political or economic developments in Canada and Chile, or other countries where the Company may carry on business in the future; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected geological or structural formations, pressures, cave-ins and flooding); risks relating to the credit worthiness or financial condition of suppliers, refiners and other parties with whom the Company does business; inadequate insurance, or inability to obtain insurance, to cover these risks and hazards; employee relations; relationships with and claims by local communities and indigenous populations; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development, including the risks of obtaining necessary licenses and permits and the presence of laws and regulations that may impose restrictions on mining; diminishing quantities or grades of mineral reserves as properties are mined; global financial conditions; business opportunities that may be presented to, or pursued by, the Company; the Company’s ability to complete and successfully integrate acquisitions and to mitigate other business combination risks; challenges to, or difficulty in maintaining, the Company’s title to properties and continued ownership thereof; the actual results of current exploration activities, conclusions of economic evaluations, and changes in project parameters to deal with unanticipated economic or other factors; increased competition in the mining industry for properties, equipment, qualified personnel, and their costs. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

BIOASIS TECHNOLOGIES INC. a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it has retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.

Kilmer Lucas combines a healthcare industry focus with a global reach. Working directly from its offices in Toronto, New York and San Francisco, and through a carefully assembled affiliate network that includes seasoned professionals based in Israel, Asia and Europe, Kilmer Lucas helps its clients to successfully navigate and penetrate the capital markets and media both at home and abroad. More information about the firm can be found at www.kilmerlucas.com.

“As biOasis continues to move aggressively forward into its commercialization phase, we are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader investor audience,” said Rob Hutchison, biOasis’ CEO.

Stephen Kilmer, President of Kilmer Lucas, commented, “We believe that a strong investment story is emerging at biOasis and we are excited that the company has chosen us to help tell it. Through the provision of a full range of investor relations and financial communications services, our primary goals will be to assist biOasis in achieving a fair and sustainable market valuation and to enhance the reputation that the company carries in the minds of investors, analysts and members of the media.”

Under the terms of the agreement, BiOasis will pay Kilmer Lucas a monthly retainer fee of C$6,500 for its services. Should BiOasis uplist its common shares for trading to a national U.S. stock exchange while this agreement is in effect, the monthly retainer fee paid by it to Kilmer Lucas will automatically increase to US$7,500. The agreement, which commences immediately, has an initial term of 60 days. Following the end of the initial term, the agreement will renew automatically for 30-day periods unless terminated by either party.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.

BioMmune Technologies Inc. is pleased to announce that it has closed its non-brokered private placement announced on May 3rd, 2015. The Company has issued 5,000,000 units (each a “Unit”) at a price of CDN$0.20 per unit, for gross proceeds of CDN$1,000,000. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$0.30 per share for a period of eighteen months up to and including December 8th, 2016,, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of $0.50 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder’s fees of CDN$70,400 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until October 9th, 2015. The net proceeds from the sale of units have been added to working capital in furtherance of the Company’s business.

ABOUT BIOMMUNE

BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. BioMmune is developing three technologies discovered at The University of British Columbia. They include, discovery of compounds that will be active in restoring immune-recognition of cancer cells resulting in the body’s immune system to fight the cancer cells. A discovery relating to Channels, whose activities regulate activity of cells involved in the immune system to improve their ability to combat cancers, infections and also autoimmunities. Furthermore, the company is pursuing the modulation of CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases. BioMmune trades on the TSX Venture Exchange under the symbol “IMU”.

SocialText is one of the easiest ways to boost your visibility online because we use search engine-friendly releases. You can include images, videos and attachments in your SocialText releases, which can make it easier for prospects and customers to find your content online.